Comparable Initial Engagement of Intracellular Signaling Pathways by Parathyroid Hormone Receptor Ligands Teriparatide, Abaloparatide, and Long-Acting PTH.

Sato, Tadatoshi; Verma, Shiv; Khatri, Ashok; Dean, Thomas; Goransson, Olga; Gardella, Thomas J; Wein, Marc N

Sato, Tadatoshi; Verma, Shiv; Khatri, Ashok; Dean, Thomas; Goransson, Olga; Gardella, Thomas J; Wein, Marc N.

Afiliação

Sato T; Endocrine Unit, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA.
Verma S; Endocrine Unit, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA.
Khatri A; Endocrine Unit, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA.
Dean T; Endocrine Unit, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA.
Goransson O; Department of Experimental Medical Science Lund University, Diabetes, Metabolism and Endocrinology Lund Sweden.
Gardella TJ; Endocrine Unit, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA.
Wein MN; Endocrine Unit, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA.

JBMR Plus ; 5(5): e10441, 2021 May.

Article em En | MEDLINE | ID: mdl-33977197

Palavras-chave

ANABOLICS; BONE MODELING AND REMODELING; CELL/TISSUE SIGNALING; CELLS OF BONE; ENDOCRINE PATHWAYS; HORMONE REPLACEMENT/RECEPTOR MODULATORS; MOLECULAR PATHWAYS; OSTEOCYTES; PTH/Vit D/FGF23; REMODELING; THERAPEUTICS

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: JBMR Plus Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google